Bevacizumab cured age-related macular degeneration (AMD) via down-regulate TLR2 pathway Abbreviations AMD -Age-related macular degeneration RPE -Retinal pigment epithelium TLR2 -The mammalian toll like receptor 2 P3C -Pam3CSK4
Introduction
Age-related macular degeneration (AMD) is the most common cause of blindness and visual impairment in people over 50 years of age [1, 2] . During the pathological progress of AMD, retinal pigment epithelium (RPE) plays a very important role in choroidal neovascularisation (CNV, also called wet AMD) for atrophy of the PRE resulting from deposits called drusen that form between the retinal pigment epithelium (RPE) and underlying choroid [3] . To date, it is commonly proposing that oxidative damage is involving in RPE dysfunction in AMD, leading to subepithelial deposits and inflammation in RPE/choroid interface [4] [5] [6] . However, further studies on the mechanism of RPE dysfunction in AMD are required.
Bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) is a full-length humanized anti-VEGF monoclonal IgG1 antibody (molecular weight 149 kDa) that inhibited the action of all isoforms of vascular endothelial growth factor. The drug was initially developed as an intravenous agent in the treatment of metastatic colorectal cancer [5] . In recent years, clinical trials have established the efficacy of Bevacizumab for the treatment of AMD [5, 6] . Bevacizumab injections with 1.25 mg in a six weekly variable retreatment regimen are superior to standard care (pegaptanib sodium, verteporfin, sham). And then this treatment improved visual acuity on average at 54 weeks [2] . Furthermore, some groups reported that the mammalian toll like receptor 2 (TLR2) pathway is activated early in the process and drives dedifferentiation of the RPE through reducing the expression of RPE-characteristic proteins. This mechanism also occurs in response to a qualitatively different insult and chemical oxidative damage. Therefore, inhibiting RPE stress response by blocking TLR2 activation has beneficial effects on the RPE and photoreceptors. Thus, understanding the mechanism by which Bevacizumab cures AMD has become increasingly critical. However, there is a lack of such knowledge in RPE or AMD Patients.
In this study, we firstly detected the role of TLR2 pathway for P3C mediated apoptosis of ARPE-19, and then, we carried out much more studies to make clear whether the same mechanism in the bevacizumab cured AMD by in vitro cultured RPE from AMD Patients.
Experimental Procedures

ARPE-19 cells culture
As described by other's inn previous studies [8] , the ARPE-19 cells were used at passages 24 to 26 and were maintained in tissue culture flasks in DMEM-F12 (Invitrogen, Carlsbad, CA) containing 2% fetal bovine serum (FBS; Invitrogen) until they were postconfluence for several weeks. Then, the cells were harvested and plated in DMEM-F12, 2% FBS on glass coverslips or laminin-coated clear filters (Transwell; Fisher Scientific, Hampton, NH) at a density of 2 x10 5 cells mL -1 . The filters subdivide the culture dish into two chambers to enable studies of transmonolayer permeability.
Preparation of Primary RPE Cell Culture from Postmortem Autopsy Eyes
AMD Donor's eyes were received through the second people hospital of Zhengzhou (Zhengzhou, China) (eyes are collected within a few hours after death and shipped in sterile physiologic solution). Donors were 60 years and above in age and included both females and males. The anterior segment from each donor eye was removed as described in previous reports [9] [10] [11] [12] . Briefly, after electron microscopy (EM) examination, RPE cells were harvested from the RPE-choroid-sclera using fine forceps. Then the RPE choroid was carefully separated from the sclera and placed face up in a small sterile Petri dish dipping with 0.1% dispase contain Ca 2+ and Mg 2+ -free Hank's balanced salt solution. After gently resuspending the cell pellet, the suspended cells were then transferred to T25 culture flasks and placed in an incubator at 37°C and 5% CO 2 under humidified atmosphere [6] [7] [8] .
DN MyD88 transfection
Dominant negative (DN) cDNA constructs of MyD88 (DN MyD88) was obtained as a gift from Guo Xing Li nad were prepared as previously described [13] . Luciferase data obtained from the cells transfected with pcDNA3 empty vector was used to assess the specificity of DN-MyD88. Briefly, ARPE-19 and primary RPE cells were plated at a concentration of 50,000 cells/well in 24-well plates and cultured in DMEM-F 12, 2% FBS on glass coverslips or laminin-coated clear filter overnight. Cells were co-transfected the following day with FuGene6 Transfection Reagent as per the manufacturer's instructions. The Roche Fugene6 transfection system does not affect the cell viability or induce cytokine production in the transfected cells. The reporter genes NF-κB -Luciferase (0.5 μg) and either empty vector or dominant negative mutants of MyD88 (0.1, 0.3 and 0.5 μg) were transfected into the ARPE-19 cells. Reporter gene NF-κB -luciferase (0.5 μg) was transfected to assess the effect of P3C (10 μmol L -1 ) on NF-κB expression. pCMV-β-galactosidase cDNA (0.1 μg) was transfected to normalize the results for transfection efficiency as described earlier [14] [15] [16] . After overnight transfection, the cells were treated with 10 μmol L -1 P3C. The luciferase activity was measured with a Promega kit (Promega, Madison, WI) and a luminometer. β-galactosidase activity as determined by calorimetric method is a well established and accepted method to assess the transfection efficiency.
MTT analysis
ARPE-19 and Primary RPE cells were diluted to 2 x10 5 cells/ ml and seeded at 0.1 ml/well in 96-well flatbottomed plates. They were randomly divided into a normal control group and two treatment groups treated with different dosages of P3C (Invivogen, Suite 100 San Diego, California, USA): 0.5, 1, 5, 10, 20 μmol L -1 , or Avastin (Bevacizumab, Genentech, USA): 5, 10, 20, 50 μg L -1 , respectively. The cultures were maintained for 24 h at 37 o C with 5% CO 2 humidified air. Then, MTT reagent (5 mg mL -1 ) was added to each well and incubated for 4 h. After the incubation, the incubation precipitates were dissolved with 0.1 ml of SDS. The optical density (OD) values were measured by spectrophotometry at 570 nm using an ELx800 Microplate Reader (Bio-Tek Instruments, Inc. Winooski, Vermont, USA).
Western blotting
After treatment, cells were briefly washed with phosphate-buffered saline (PBS) and then lysed in 1× sodium dodecylsulfate (SDS) loading buffer on ice. Lysates were centrifuged at 15,000 x g for 10 min at 4°C. Protein concentrations were determined by the Bradford assay with bovine serum albumin as standard (Bio-Rad, Hercules, CA, USA). Equivalent amounts of protein (20-50 μg) were separated by 12% SDSpolyacrylamide gels and transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). Following incubation with PBS containing 0.05% Tween 20 and 5% non-fat dry milk to block non-specific binding, membranes were incubated with primary antibodies, then with appropriate secondary antibodies conjugated to horseradish peroxidase. Immunoreactive bands were visualized by using chemiluminescence methods. The blots for detected proteins were quantified using Multi Gauge Image Analysis software (FujiFilm, Japan) and were normalized using β-actin as an internal control. The following antibodies were used: TLR2, Caspase-3, Cleaved-caspase-3, My D88, NF-κB, IKK, p-IKK and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Statistical analysis
Statistical analyses were performed using the SPSS software. Differences between groups were evaluated by one-way analysis of variance (ANOVA) with Tukey's test. P values of less than 0.05 were considered to indicate statistical significance.
Results
ARPE-19 and Primary RPE cells aPoPtosis in vitro
As shown in Figure 1A , the apoptosis rate of ARPE-19 gradually increased when treated with P3C with an IC50 value of 10 μmol L -1 P3C after 24 h in culture. However, the apoptosis rate of Primary RPE cells gradually decreased when treated with Bevacizumab dose ( Figure 1B ).
P3C active TLR2 Pathway during ARPE-19 aPoPtosis
To examine the role of TLR2 pathway in P3C treated ARPE-19 in vitro, we used Western blotting analysis to detect the changes in the TLR2 pathway. As shown in Figure 2A , the protein expression of TLR2, My D88, NF-κB, p-IKK in P3C treated group were significantly up-regulated and higher than the control group respectively. Furthermore, the expression of Caspase-3 and Cleavead-caspase-3 was significantly up-regulated and higher than the control group ( Figure 2B ). Taken together, these results indicate that P3C active the TLR2 pathway during ARPE-19 apoptosis.
DN My D88 inhibit ARPE-19 cells apoptosis resulting from P3C
TLR2 activation is generally mediated by an intracellular adaptor, myeloid differentiation primary response protein 88 (MyD88) [14] . As shown in Figure 3A inhibition of MyD88 dimerization, using different doses DN My D88, the high expression of NF-κB with high luciferase activity induced by P3C was significantly inhibited (P<0.01, P<0.001, respectively). Inhibition of MyD88 dimerization also reduced apoptosis in ARPE-19 cells that were treated with 10 μmol L -1 P3C (Figure 3B ), In addition, the expression of My D88, NF-κB, p-IKK is significantly down-regulated when MyD88 dimerization was inhibited ( Figure 3C ). Furthermore, after treatment with DN My D88, the expression of Caspase-3, Cleaved-caspase-3 were markedly decreased in ARPE-19 cells treated with 10 μmol L Figure 3D ). These findings suggesting that MyD88 is involved in the TLR2 effect on ARPE-19 cells apoptosis resulting from P3C treatment.
P3C (
Bevacizumab inhibit primary RPE Cell apoptosis from Postmortem Autopsy Eyes
Western blot analysis was used to detect the changes in TLR2 pathway in primary RPE cells from AMD patients. Interestingly, the expression of My D88, NF-κB, p-IKK in primary RPE Cells from AMD patients after treated with Bevacizumab 50 μg L -1 was significantly downregulated ( Figure 4A ). However, there is no statistical different in the expression of TLR2 pathway between Bevacizumab 50 μg L -1 treated group and DN MyD88 transfection primary RPE Cells from AMD patients and then Bevacizumab 50 μg L -1 treated group ( Figure 4A ). Furthermore, the expression of Caspase-3, Cleavedcaspase-3 were markedly decreased in the same group ( Figure 4B ). Therefore, these results suggested that Bevacizumab cured age-related macular degeneration (AMD) via down-regulation of Toll-like receptor 2 (TLR2) pathway in retinal pigment epithelium (RPE) from AMD patients
Discussion
In the current study, we show that MyD88 is involved in TLR2 pathway and P3C mediated apoptosis in ARPE-19 cells. And more importantly, our findings suggest that Bevacizumab cured age-related macular degeneration (AMD) via down-regulation of Toll-like receptor 2 (TLR2) pathway in RPE from AMD patients.
During the development of AMD, the RPE in the macular region undergoes hypopigmentation, depigmentation, or apparent absence of the RPE in the macular area [13, 14] . Therefore, we used the P3C mediated apoptosis of ARPE-19 cells (RPE cell line) as a model to explore the mechanism. In our study, we found that TLR2 pathway in the ARPE-19 cells treated with P3C were active and then inhibited by DN MyD88 transfection which is the important protein in the TLR2 pathway. These results suggest that P3C activated TLR2 pathway during ARPE-19 apoptosis. Furthermore, we found that TLR2 pathway in the primary AMD RPE cells were active and then inhibited by DN MyD88 transfection which is the important protein in the TLR2 pathway. Our findings were consistent with other groups that report TLR2 signaling in RPE cells may play an important role in innate and adaptive immune responses, apoptosis within the retina [17] [18] [19] . An important finding is that TLR2 pathway activation will result in RPE apoptosis in AMD.
Bevacizumab is approved for the treatment of advanced colorectal cancer (CRC), advanced nonsmall cell lung cancer (NSCLC), metastatic breast cancer (MBC), and advanced renal cell cancer and diseases related to TLR2 pathway [4, 20] . However, increasing number of studies indicated that bevacizumab is commonly used for the treatment of neovascular AMD and had equivalent effects on visual acuity when administered according to the same schedule compared to ranibizumab [21] [22] [23] . On the other hand, TLR2 activity usually leads to the activation of nuclear factor (NF)-κB [15] . NF-κB exists in several dimeric forms, predominantly the p50/p65 heterodimer. Translocation of NF-kB to the nucleus16 is regulated by the phosphorylation of I-kappa-B kinase (IKK). In our studies, we found that the expression of My D88, NF-κB and p-IKK in primary RPE Cells from AMD patients after DN MyD88 transfection is significantly down-regulated. Interestingly, the expression of My D88, NF-κB and p-IKK in primary RPE Cells from AMD patients after treatment with Bevacizumab 50 μg L -1
were also significantly down-regulated. Therefore, our data shown that mammalian toll like receptor 2 (TLR2) pathway is activated early in the process and drives dedifferentiation of the RPE through reduction in expression of RPE-characteristic proteins. However, these results suggest that Bevacizumab cured age-related macular degeneration (AMD) via downregulate Toll-like receptor 2 (TLR2) pathway in retinal pigment epithelium (RPE) from AMD patients.
